Sugi Predict

Sugi Predict / Compounds / SCHEMBL177568

SCHEMBL177568

SCHEMBL177568

Cc1cc(OBOc2ccc(F)c(C)c2)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 2/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ ACHE P22303 1/20 0.36
▸ HTR2C P28335 2/20 0.34
▸ HTR2B P41595 2/20 0.34
▸ PTGS2 P35354 2/20 0.32
▸ CHEK2 O96017 1/20 0.32
▸ EPAS1 Q99814 1/20 0.32
▸ MAPK14 Q16539 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ TNF P01375 1/20 0.31
▸ MAOA P21397 1/20 0.31
▸ MAOB P27338 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16303468 0.83 HTR2A (0.38) HTR2ASLC6A4KCNH2ACHEHTR2C
SCHEMBL450533 0.83 MRGPRX4 (0.39) SLC6A4ACHERAB9AKMT2A
SCHEMBL177356 0.79 TDP1 (0.44) HTR2ASLC6A4RAB9AKMT2A
SCHEMBL29804592 0.79 TDP1 (0.44) HTR2ASLC6A4RAB9AKMT2A
SCHEMBL177743 0.79 SOS1 (0.41) HTR2ASLC6A4MAOAMAOB
SCHEMBL29555340 0.77 RAB9A (0.46) HTR2ASLC6A4KCNH2ACHEMAPK14
SCHEMBL168299 0.77 RAB9A (0.46) HTR2ASLC6A4KCNH2ACHEMAPK14
SCHEMBL12094745 0.76 HTR2A (0.41) HTR2ASLC6A4KCNH2ACHEHTR2C
SCHEMBL1047284 0.76 HTR2A (0.41) HTR2ASLC6A4KCNH2ACHEHTR2C
SCHEMBL22472 0.75 CA12 (0.43) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 — — US disclosed
CN-120077035-A As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 阿斯利康(瑞典)有限公司 2025-05-30 — — CN disclosed
CN-115003295-B Novel chroman derivatives having estrogen receptor degrading activity and uses thereof 冰洲石生物科技公司 2025-05-06 — — CN disclosed
CN-113493420-B EGFR tyrosine kinase inhibitor and application thereof 南京迈晟科技有限责任公司 2025-04-25 — — CN disclosed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 — — EP disclosed
CN-114728949-B Heterocyclic compounds as kinase inhibitors and uses thereof 曙方医药 2024-11-12 — — CN disclosed
CN-114989164-B Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof 詹森药业有限公司 2024-08-13 — — CN disclosed
CN-118239931-A As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-06-25 — — CN disclosed
CN-114269432-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 — — CN disclosed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO disclosed
EP-1358165-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-05 — — EP disclosed
US-20030191311-A1 A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease EVOTEC INTERNATIONAL GMBH (DE) 2003-10-09 — — US disclosed
US-20030187268-A1 Imidazole derivatives EVOTEC INTERNATIONAL GMBH (DE) 2003-10-02 — — US disclosed
US-6610723-B2 Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration HOFFMANN-LA ROCHE INC. 2003-08-26 — — US disclosed
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia SMITHKLINE BEECHAM CORPORATION 2003-05-01 — — US disclosed
EP-1244446-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2003-01-08 — — EP disclosed
US-20020151715-A1 Imidazole derivatives EVOTEC INTERNATIONAL GMBH (DE) 2002-10-17 — — US disclosed
EP-1244446-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2002-10-02 — — EP disclosed
WO-2002060877-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-08-08 — — WO disclosed
WO-2001039773-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia MPL, THPO, TPO HTR2A 815/4885SLC6A4 2514/4885KCNH2 3837/4885
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SCNN1B, SCN1B, SCN2B HTR2A 1313/4885SLC6A4 146/4885KCNH2 44/4885
US-20030191311-A1 A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease GRIN1, GRIN2B, GRIN3B HTR2A 226/4885SLC6A4 667/4885KCNH2 592/4885
US-20020151715-A1 Imidazole derivatives GRIN2B, GRIN1, GRIN2A HTR2A 901/4885SLC6A4 295/4885KCNH2 352/4885
US-20030187268-A1 Imidazole derivatives GRIN2B, GRIN1, GRIN2A HTR2A 901/4885SLC6A4 295/4885KCNH2 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.